8-K: Intellia Therapeutics Announces Positive Phase 2 Results for NTLA-2002 in Hereditary Angioedema

Intellia Therapeutics reports positive Phase 2 results for NTLA-2002, a CRISPR gene editing therapy, showing significant reductions in hereditary angioedema attacks.

Summary

• Intellia Therapeutics announced positive Phase 2 data for NTLA-2002, an investigational CRISPR-based gene editing therapy for hereditary angioedema (HAE).
• The study was a randomized, double-blind, placebo-controlled trial with 27 participants receiving either a 25 mg or 50 mg dose of NTLA-2002 or a placebo.
• The data cut-off was April 4, 2024, when the 25th patient completed the 16-week primary observation period.
• Patients receiving a single dose of NTLA-2002 experienced significant reductions in HAE attack rates.
• The 50 mg dose resulted in a 77% reduction in mean monthly attack rates compared to placebo during weeks 1-16, and an 81% reduction during weeks 5-16.
• Eight out of 11 patients in the 50 mg arm experienced a complete response with no attacks during the 16-week primary observation period and remained attack-free through the latest follow-up (median of eight months).
• The 50 mg dose also achieved an 86% mean reduction in kallikrein protein from baseline at week 16, compared to 55% in the 25 mg arm.
• NTLA-2002 was well tolerated at both dose levels, with the most frequent adverse events being headache, fatigue, and nasopharyngitis.
• There were no serious adverse events related to the treatment, except for one serious adverse event in the placebo arm.
• Based on these results, Intellia has selected the 50 mg dose for evaluation in the global, pivotal Phase 3 HAELO study.

Sentiment

Score: 9

Explanation: The document presents very positive results from a Phase 2 trial, with strong efficacy and safety data, suggesting a high likelihood of success for the therapy. The potential for a one-time treatment is a major positive.

Positives

• NTLA-2002 shows potential as a one-time treatment for HAE, offering a possible functional cure.
• The 50 mg dose demonstrated a high rate of complete response, with 8 out of 11 patients attack-free.
• The treatment was well-tolerated with no serious adverse events related to the treatment.
• The results are consistent with long-term Phase 1 data.
• The study results were published in The New England Journal of Medicine.

Negatives

• One patient in the placebo arm experienced a serious adverse event of Grade 4 edema of the tongue with breathing impairment.
• The study had a limited number of participants (27), which may affect the generalizability of the results.

Risks

• The success of NTLA-2002 is subject to risks related to intellectual property protection.
• There are risks associated with third-party relationships, including licensors and licensees.
• The authorization, initiation, enrollment, and conduct of studies for NTLA-2002 are subject to uncertainties.
• There is a risk that NTLA-2002 may not be successfully developed and commercialized.
• The results of clinical studies may not be predictive of future results.

Future Outlook

Intellia is actively screening patients for the global, pivotal Phase 3 HAELO study evaluating the 50 mg dose of NTLA-2002, with the potential for NTLA-2002 to become the first one-time treatment for HAE and a functional cure.

Management Comments

• Intellia President and Chief Executive Officer John Leonard, M.D., stated that the positive Phase 2 results underscore the tremendous potential of their in vivo CRISPR gene editing therapy to be a functional cure and redefine the treatment paradigm for HAE.
• Danny Cohn, M.D., Ph.D., the Phase 2 study's lead principal investigator, expressed optimism that NTLA-2002 will change the way HAE is treated and end the need for a lifetime of chronic treatment.

Industry Context

This announcement is significant as it highlights the potential of CRISPR gene editing technology to provide a one-time treatment for a rare genetic disease, potentially disrupting the current treatment paradigm that relies on chronic therapies. This could position Intellia as a leader in the gene editing space for rare diseases.

Comparison to Industry Standards

• Current HAE treatments often require chronic administration, either intravenously, subcutaneously, or orally, and do not always eliminate all attacks.
• NTLA-2002's potential to provide a one-time treatment with a high rate of complete response sets it apart from existing therapies.
• Companies like CSL Behring and Takeda offer prophylactic and on-demand treatments for HAE, but these require ongoing administration.
• The 86% mean reduction in kallikrein protein achieved with the 50mg dose is a significant improvement compared to the efficacy of existing treatments.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical results.
• Patients with HAE may have a new, potentially curative treatment option.
• Employees of Intellia may be motivated by the positive progress of the therapy.
• The results could impact competitors in the HAE treatment market.

Next Steps

• Intellia will continue to screen patients for the global, pivotal Phase 3 HAELO study.
• The company will present the Phase 2 results at the 2024 American College of Allergy, Asthma & Immunology (ACAAI) Scientific Meeting.

Key Dates

Keywords

Hereditary Angioedema, NTLA-2002, CRISPR, Gene Editing, Clinical Trial, Phase 2, Phase 3, Kallikrein, In Vivo, Therapy